Ionis Pharmaceuticals Inc (IONS) stock is down 6.59% over the past week and gets a Bearish rating from InvestorsObserver's Sentiment Indicator.
What is Stock Sentiment?
In investing, sentiment generally means whether or not a given security is in favor with investors. It is typically a pretty short-term metric that relies entirely on technical analysis. That means it doesn’t incorporate anything to do with the health or profitability of the underlying company.
Changes in price are generally the best indicator of sentiment for a particular stock. At its core, a stock's trend indicates whether current market sentiment is bullish or bearish. Investors must be bullish if a stock is trending upward, and are bearish if a stock is moving down.
InvestorsObserver's Sentiment Indicator factors in both price changes and variations in volume. An increase in volume usually means a current trend is stengthening, while a drop in volume tends to signal a reversal to the ongoing trend.
Our system also uses the options market in order to receive additional signals on current sentiments. We take into account the ratio of calls and puts for a stock since options allow an investor to bet on future changes in price.
What's Happening With IONS Stock Today?
Ionis Pharmaceuticals Inc (IONS) stock is trading at $47.91 as of 11:16 AM on Thursday, Sep 24, a loss of -$1.42, or -2.88% from the previous closing price of $49.33. The stock has traded between $47.86 and $49.36 so far today. Volume today is less active than usual. So far 235,609 shares have traded compared to average volume of 778,130 shares.
To see InvestorsObserver's Sentiment Score for Ionis Pharmaceuticals Inc click here.
More About Ionis Pharmaceuticals Inc
Ionis Pharmaceuticals is the leading developer of antisense technology to discover and develop novel drugs. Ionis' broad clinical and preclinical pipeline treats a wide variety of diseases, with an emphasis on cardiovascular, metabolic, severe, and rare diseases. Ionis sold rights to its first product, Kynamro, to Kastle Therapeutics after lackluster commercial success, but with partner Biogen brought its second drug, Spinraza for spinal muscular atrophy, to market. ATTR amyloidosis drug Tegsedi (inotersen) was approved in 2018 and cardiology drug Waylivra was approved in Europe in 2019.
Click Here to get the full Stock Score Report on Ionis Pharmaceuticals Inc (IONS) Stock.
